Market Cap: $280.08K
SL
Scinai Immunotherapeutics Ltd.
SCNI
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $280.08K
Scinai Immunotherapeutics Ltd. has successfully completed a strategic reorganization, paving the way for the launch of Scinai Biopharma Services Ltd., a dedicated Contract Development and Manufacturin…
Scinai Immunotherapeutics Streamlines Operations with New CDMO Platform Scinai Immunotherapeutics Ltd. has recently completed a strategic corporate reorganization that has given birth to a dedicated c…
Scinai Immunotherapeutics: Strengthening Presence in Global Biopharmaceutical Landscape Scinai Immunotherapeutics Ltd., a biopharmaceutical company focused on innovative inflammation and immunology th…
Scinai Immunotherapeutics Faces Nasdaq Compliance Challenge Scinai Immunotherapeutics Ltd., a biopharmaceutical firm specializing in innovative immunotherapy solutions, finds itself navigating a compl…
Scinai Immunotherapeutics Faces Nasdaq Compliance Challenge Amid Innovative Developments Scinai Immunotherapeutics Ltd. is currently navigating a critical compliance issue with the Nasdaq Capital Mark…
Scinai Immunotherapeutics Faces Compliance Challenge with Nasdaq; Focus on Innovative Therapies Continues On March 12, 2026, Scinai Immunotherapeutics Ltd. receives a notification from the Nasdaq List…
Scinai Immunotherapeutics Secures Funding for Advanced Manufacturing Technology Scinai Immunotherapeutics Ltd. has recently announced a significant advancement in its manufacturing capabilities, follo…
Robotic Aseptic Technology to Revolutionize Scinai Immunotherapeutics’ Manufacturing Capabilities Scinai Immunotherapeutics Ltd. announces significant strides in its manufacturing capabilities by secu…
Robotic Aseptic Fill and Finish Platform Receives Major Support from Israel Innovation Authority Scinai Immunotherapeutics Ltd. announces a significant advance in its manufacturing operations with exp…
Strengthening Israel’s Biopharma Infrastructure: Scinai Immunotherapeutics Takes the Lead Scinai Immunotherapeutics Ltd., a biopharmaceutical company specializing in inflammation and immunology therap…
Strengthening Israel's Biopharma Ecosystem: Scinai Immunotherapeutics Takes Center Stage Scinai Immunotherapeutics Ltd. is poised to play a significant role in the future of Israel's biopharmaceutical…
Scinai Immunotherapeutics to Address Biopharma Manufacturing Challenges at HealthIL Week 2026 Scinai Immunotherapeutics Ltd., a biopharmaceutical company specializing in inflammation and immunology th…
I apologize, but it appears that the text you intended to provide for summarization is missing. Please share the content, and I will gladly assist you in creating the summary as per your requirements.
Scinai Immunotherapeutics Advances in Cancer Treatment with Novel Clinical Trials Scinai Immunotherapeutics announces significant strides in its clinical research aimed at enhancing cancer treatment e…
Scinai Immunotherapeutics Advances in Cancer Treatment with Innovative Immunotherapy Approach Scinai Immunotherapeutics is making significant strides in the field of cancer treatment through its pione…
Scinai Immunotherapeutics Advances Cancer Treatment with Innovative Therapy Scinai Immunotherapeutics is making significant strides in the field of cancer treatment with its novel immunotherapy approa…
Scinai Immunotherapeutics Strengthens Biopharma Manufacturing with New Grant Scinai Immunotherapeutics Ltd., a Jerusalem-based biopharmaceutical company, secures a significant non-dilutive grant of ap…
Scinai Immunotherapeutics Secures Funding to Enhance Local Biopharma Manufacturing Capabilities Scinai Immunotherapeutics Ltd., a Jerusalem-based biopharmaceutical company, receives significant backin…